U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07267338) titled 'Pembrolizumab + MRGOO3 as Neoadjuvant in NPC' on July 17.
Brief Summary: The goal of this clinical trial is to evaluate efficacy and safety of neoadjuvant of the anti PD1 agent Pembrolizumab combined with MRG003 and adjuvant treatment of Pembrolizumab in patients with Epstein-Barr virus (EBV) - associated locoregionally advanced nasopharyngeal carcinoma.
The expected sample size is 35 patients.
Participants will receive 3 cycles of neoadjuvant pembrolizumab 200mg Q3W plus MRG003 2.3mg/kg Q3W followed by the standard concurrent chemoradiotherapy. Then participants will receive 14 cycles of adjuvant Pembrolizumab 200 mg Q3W after the...